To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
149 Current news about the topic melanomarss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
VPM organizes clinical development - Initial focus on prostate cancer
Braunschweig/Munich/New York. Vakzine Projekt Management GmbH (VPM), Braunschweig, Germany, has obtained from Memorial Sloan-Kettering Cancer Center a worldwide exclusive license for several patents covering a range of recombinant cell lines. These cell lines have a high potential to ...
Gaitersburg. MedImmune, Inc. and Cerus Corporation announced preclinical results demonstrating the effectiveness of a novel therapeutic vaccine technology in suppressing the growth of certain tumors. These results will be presented at the 95th Annual Meeting of the American Association for Cancer ...
Munich Biotech AG has announced details of results presented during a recent congress of clinical investigators, reporting on results of Phase I trials of MBT-0206 in cancer patients. New results have indicated that patients continuing with MBT-0206 beyond the trial period on compassionate ...
Astex Technology, the fragment-based drug discovery company, together with The Wellcome Trust, the Institute of Cancer Research and Cancer Research Technology announced an exclusive collaboration relating to the discovery of novel drugs against the cancer target BRAF. BRAF was first identified ...
Scientists Identify Immunoregulatory Mechanism to Fight Cancer and Infectious Diseases
TORONTO, -- Generex Biotechnology Corporation announced the recent presentation of a poster at the Keystone Symposium, "Rational Design of Vaccines and Immunotherapies" in Colorado, on a novel cancer vaccination method developed by scientists and collaborators at its Antigen Express subsidiary. ...
Phase I Clinical Trial on Array's Lead MEK Inhibitor Targeted for 2004
Array BioPharma and AstraZeneca announced a licensing and collaboration agreement to develop Array's MEK program in the field of oncology. The program includes the clinical development candidate (ARRY-142886) and related intellectual property. Under the agreement, Array will receive an upfront ...
Generex Biotechnology Corporation announced that the National Cancer Institute has awarded a Small Business Innovative Research (SBIR) grant to support development of a novel vaccine for T- helper cell-stimulating peptide vaccines to treat malignant melanoma. The research will be carried out by ...
Epimmune Inc., and Anosys, Inc. announced that they have preliminarily agreed to merge their operations to create a combined company focused on the field of immunotherapeutics and products for the treatment of cancer and infectious diseases. The all-stock transaction is subject to the parties ...
Abbott Park, and Downers Grove, Illinois, October 24, 2001 — Abbott Laboratories and Vysis, Inc. announced that the companies have entered into a definitive agreement for Abbott to acquire Vysis, a leading genomic disease management company that develops and markets clinical laboratory products, ...